Document:

THE DECEMBER 20, 2012 AMENDMENT AND
RESTATEMENT

OF THE

MARCH 12, 2012 ECOTALITY/USABB “BLINK
LICENSE AGREEMENT”

 

- EXECUTION
VERSION -

 

 

Effective December 20, 2012 (the “Amendment
Effective Date”), ECOtality, Inc., a Nevada corporation (“ECOtality”), ABB Inc., a Delaware corporation
(“USABB”), and ABB Technology Ltd., a Swiss entity (“CHTET”), mutually agree to amend and
restate the March 12, 2012 ECOtality/USABB “Blink License Agreement” (the “Agreement”) as follows,
via this amendment and restatement to the Agreement (this “Amendment”) ,with CHTET substituted for USABB.

 

WHEREAS:

 

A.ECOtality and USABB entered
into the Agreement on March 12, 2012 (the “Effective Date”), but due to certain policies and practices of the
ABB Group of affiliated companies (“ABB”), of which both USABB and CHTET are members, USABB now wishes to assign
the Agreement to CHTET (the “Assignment”);

 

B.The Agreement’s Section
9.2 (MISCELLANEOUS; Assignment) requires ECOtality’s prior consent for the Assignment;

 

C.ECOtality has no objections
to the Assignment and hereby consents to the Assignment;

 

D.CHTET accepts the Assignment
from USABB and agrees to be fully bound under the Agreement to ECOtality; and

 

E.Upon mutual execution of
this Amendment, ECOtality and CHTET agree that the text of the Agreement shall consist solely of the terms and conditions of this
Amendment.

 

THEREFORE: ECOtality, USABB, and
CHTET mutually agree as follows.

 

1.ECOtality consents to the
Assignment, without any reservation.

 

2.As part of the Assignment:

 

a.USABB assigns to CHTET all
of USABB’s rights and obligations under the Agreement, without any reservation; and

 

b.CHTET accepts all of USABB’s
rights and obligations under the Agreement, without any reservation.

 

3.Effective as of the Amendment
Effective Date:

 

a.CHTET is substituted for
USABB in the Agreement and CHTET becomes the sole ABB counterparty to the Agreement; and

 

b.The
Agreement’s terms and conditions consist exclusively and entirely of the following terms and conditions, with ECOtality
and CHTET referred to herein from time to time individually as a “Party” and collectively as the “Parties.”
Affiliates of either Party shall be referred to herein as “Affiliates,” with CHTET and its Affiliates referred
to herein as the “ABB Group.”

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
2  of 14

 

 

TABLE OF CONTENTS

 

	RECITALS	4.34 – Protection of Intellectual Property
	1 – LICENSE	Rights
	1.1 – Grant	5 – INDEMNIFICATION
	A – The Blink API License	5.1 – Indemnification Obligations
	B – The Licensed Patents’ License	5.2 – Procedure
	1.2 – Restrictions and Reservations	5.3 – Survival
	1.3 – License Fee; No Royalties	6 –CONFIDENTIAL INFORMATION
	A – One Time License Fee	7 – TERMINATION
	B – Royalty-Free	7.1 – Termination by ECOtality
	2 – TERM	7.2 – Effect of Termination
	3 – REPRESENTATIONS AND WARRANTIES;	8 – RESOLUTION OF DISPUTES
	DISCLAIMERS; AND LIMITATIONS	9 – MISCELLANEOUS
	3.1 – Representations, Warranties, and Covenants	9.1 – Entire Agreement
	of ECOtality	9.2 – Assignment
	3.2 – Representations, Warranties, and	9.3 – Severability
	Covenants	9.4 – Waiver
	3.3 – Disclaimer of Warranties	9.5 – Relationship of the Parties
	3.4 – Limitation of Liability	9.6 – Governing Law
	4 – LICENSE COVENANTS	9.7 – Notices
	4.1 – Reports	9.8 – Counterparts
	4.2 –Quality Standards and Controls for Use	 
	 of Marks	EXHIBIT A – THE LICENSED PATENTS

 

 

 

RECITALS

 

A.CHTET is a member of the ABB Group
as is its affiliate, ABB Inc., a Delaware corporation (“USABB”).

 

B.ECOtality and USABB are parties
to:

 

(i)A Collaboration and
Strategic Supplier Relationship Framework Agreement (the “Framework Agreement”), and

 

(ii)A Collaboration and
Strategic Supplier Relationship for NAM Agreement (the “NAM Agreement” and, together with the Framework Agreement,
the “Collaboration Agreements”),

 

each dated January 10, 2011. ECOtality
and USABB have an amended and restated Framework Agreement that amends and restates both the Framework Agreement and the NAM Agreement
into one document, dated as of the Effective Date (the “Restated Collaboration Agreement”), which was executed
concurrently with the Agreement.

 

C.The “Blink Functionality”
is the networking functionality of ECOtality associated with electric vehicle charging systems (“EV Charging Systems”)
including consumer-oriented networking functionality, and service and maintenance monitoring functionality, which is embodied in
ECOtality’s associated intellectual property. The Blink Functionality can be modified or changed, from time to time, by ECOtality,
in its absolute sole discretion

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
 3 of 14

 

D.As part of the Blink Functionality,
ECOtality has developed a proprietary application programming interface and platform that enables software programs (subject to
hardware limitations and such other requirements and specifications set forth therein) to provide some or all of the Blink Functionality
(the “Blink API”), which may facilitate information sharing, demand response, charging reservations, home energy
management, memberships, payments, load management, mapping, and media communications.

 

D.ECOtality also owns or has rights
to use certain (and in the future may own or acquire rights to use additional) registered and unregistered trademarks, service
marks, logos and other such marks that ECOtality has associated with, may elect to associate with or intends to associate with
the Blink Functionality and the Blink API(collectively, the “Marks”).

 

E.Under the Restated Collaboration
Agreement, the ABB Group has certain rights to market and sell components (“ABB Components”), assemblies (“ABB
Assemblies”), charging units (“ABB Charging Units”), and systems (the “ABB EV Charging Systems”)
for ECOtality’s EV Charging Systems. The ABB Components, the ABB Assemblies, the ABB Charging Units, and the ABB EV Charging
Systems are each an “ABB Product,” and collectively “ABB Products.”

 

F.In conjunction with the Restated
Collaboration Agreement, CHTET has requested a license to the Blink API for CHTET, with the right for the CHTET to sublicense the
Blink API to its Affiliates, and the Sublicensees (as this term is defined below in Section 1.1(a) (LICENSE, Grant, The Blink API
License), (with the ABB Group, and the Sublicensees’ collectively, the “Licensee Group”) to use in connection
with ABB Products so that such ABB Products can be activated by their hosts or end users to utilize the Blink Functionality, and
ECOtality is willing to grant the requested license under the terms and conditions set forth below.

 

NOW, THEREFORE, in consideration
of the foregoing recitals, the mutual covenants contained herein, and other good and valuable consideration, the adequacy of which
is hereby acknowledged, the Parties hereby agree as follows:

 

1.License

 

1.1Grant.

 

(a)The Blink API License

 

ECOtality hereby grants to
CHTET, a non-exclusive, non-transferable right and license (the “Blink API License”), except to CHTET’s
Affiliates and Sublicensees, as permitted by this Agreement, during the Term (as defined below) and subject to the restrictions
and reservations set forth in Section 1.2 (LICENSE; Restrictions and Reservations) below, as follows:

 

(i)At the sole discretion
of the ABB Group, to use the Blink API to develop software applications to be incorporated into the ABB Products, to be marketed
and sold in NAM, so that hosts and users of such ABB Products have the ability to activate the Blink Functionality (with such ABB
Products enabled with the Blink API software referred to herein as the “Covered Products”);

 

(ii)To use the Marks in
connection with the marketing and sale of the Covered Products, to the extent that the Licensee Group markets and sells the Covered
Products;

 

(iii)For CHTET to grant
sublicenses with respect to the rights granted under (i) and

(ii) above to CHTET’s Affiliates; and

 

    	 

    	 

    

 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
4 of 14

 

 

(iv)With the prior written
approval of ECOtality, for any member of the ABB Group to grant sublicenses with respect to the rights granted under (i) and (ii)
above to third parties in NAM for the purpose of furthering the sale of the Covered Products, which approval shall not be unreasonably
withheld (any third party so approved as a sublicensee being referred to herein as a “Sublicensee”).

 

(b)The Licensed Patents’
License

 

Subject to the terms and conditions
set forth in this Agreement, ECOtality hereby grants to CHTET and all other members of the ABB Group, via CHTET’s sublicensee
to such members of the ABB Group, a limited, worldwide, non-exclusive license (without the right to sublicense, and without the
right to assign), to the “Licensed Patents,” delineated in Exhibit A (THE LICENSED PATENTS) attached hereto,
to practice, make and use the inventions, ideas and information embodied therein for any of the ABB Products solely in connection
with the businesses of the ABB Group. The Parties’ expressly and specifically agree that the Licensed Patents granted herein
are personal to CHTET, and shall be limited to, shall not be used except as permitted by this Agreement. Notwithstanding anything
else to the contrary in this Agreement, the Licensed Patents’ license is limited to the territory or jurisdiction in which
such registered patent has been issued, except in the China and Australia markets.

 

1.2Restrictions and
Reservations 

 

(a)No member of the Licensee
Group shall have any right to modify, adapt, or change:

 

(1)The Blink API,

 

(2)The Marks, or

 

(3)The Licensed Patents

 

in any way whatsoever, except
to incorporate the software based on the Blink API in the Covered Products or, in connection with the Licensed Patents, to otherwise
use them as set forth in this Agreement. Except for these permitted uses, the Licensee Group shall not reverse assemble, reverse
compile or reverse engineer any portion of the Blink Functionality, including the Blink API, or the Licensed Patents whatsoever.

 

(b)The activation of any
Blink Functionality in any Covered Product by a host or user of such Covered Products shall be subject to such terms and conditions
(“Blink Contracts”) as ECOtality, in its sole discretion, may impose generally on hosts or users of these Covered
Products. In no event, however, shall the Licensee Group be required to have its customers for the Covered Products subject to
a mandatory activation with ECOtality of the Blink Functionality, either via a Blink Contract or otherwise. No member of the Licensee
Group shall have any independent right to activate (or permit the activation of the Blink Functionality within the Covered Products,
and no member of the Licensee Group shall have any right or interest, financial or otherwise, in the relationship between ECOtality
and any hosts or users of the Covered Products’ Blink Functionality. For the avoidance of doubt, the Blink API License granted
hereunder is solely to permit the Licensee Group to enable the hosts and users of the Covered Products to activate and utilize
the Blink Functionality (via a Blink Contract), so that such hosts and users may obtain the benefits of the Blink Functionality,
including by way of example, but without limitation and/or obligation, demand response, charging reservations, home energy management,
and media communications. Control and ownership of, and access to, any and all data, information, and communications generated
by the Covered Products, due to the associated host or user’s usage of the Blink Functionality, via the Covered Products,
shall be governed entirely by the terms and conditions of the Blink Contracts, and no member of the Licensee Group shall have any
rights, under this Agreement, to any of that data, information or communications.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
 5 of 14

 

 

(d)The license granted hereunder
is non-exclusive. ECOtality expressly reserves the unfettered right and discretion to use, and to authorize others to use, any
portion of the Blink Functionality, the Blink API, the Licensed Patents and the Marks anywhere and in any way.

 

(e)All rights not granted
herein are expressly reserved to ECOtality. Nothing in this Agreement shall be deemed to constitute the grant of any license or
other right to, or to use, the Blink API, Blink Functionality or the Licensed Patent, except as expressly set forth herein.

 

(f)Neither ECOtality nor
any of its affiliates is required to file any patent application, or to secure any patent or patent rights, or to maintain any
Licensed Patents in force. Payment of maintenance fees and the taking of any other appropriate maintenance action for the Licensed
Patents shall be at the sole discretion of, and is the financial responsibility of, ECOtality; provided, however,
that ECOtality agrees that if ECOtality elects not to pay maintenance fees and/or take any and all other appropriate maintenance
action for the Licensed Patents, ECOtality will give CHTET written notice of such decision at least three (3) months prior to the
date that appropriate maintenance action must be taken, in which case, if ECOtality decides not to maintain such patent application,
CHTET will have the option of assuming the ownership of such Licensed Patents and maintaining the application or registration to
such Licensed Patents and ECOtality shall forthwith execute any necessary documents or instruments for transferring and assigning
all right, title and interest that ECOtality has in such Licensed Patents to CHTET at CHTET’s cost and expense. If CHTET
does not take such maintenance action before the deadline for taking such action, then such Licensed Patents will be permitted
to lapse.

 

1.3License Fee; No
Royalties

 

(a)One-Time License Fee.

 

As full consideration for
the rights granted by the Agreement and this Amendment, ECOtality has received from USABB, as of the Effective Date, a one-time,
single license fee, the non-refundable sum of FIVE MILLION U.S. DOLLARS ($5,000,000) (the “License Fee”).

 

(b)Royalty-Free.

 

As the License Fee was paid
on the Effective Date and there is no additional fee required by ECOtality for this Amendment, CHTET shall not be required to pay
any royalties, other fees, or other such payments for the rights granted hereunder. Nothing herein shall be deemed to restrict
ECOtality’s ability to charge fees or otherwise collect royalties or any other amounts from hosts or users of the Blink Functionality
or in connection with the Blink Contracts.

 

2.Term.

 

(a)The term of this Agreement
(the “Term”) is from the Effective Date and shall continue indefinitely unless earlier terminated as provided
in Section 8 (TERMINATION), or by mutual agreement of the Parties.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
 6 of 14

 

(b)Regardless of any such
termination, however, all Covered Products sold by the Licensee Group prior to the termination date shall be permitted to continue
to be enabled for activation by the hosts or users of such Covered Products for access to or use of the Blink Functionality as
contemplated in this Agreement, in perpetuity, subject to the terms of the Blink Contracts with respect to such access or use.

 

3.Representations and Warranties;
Disclaimers; and Limitations.

 

3.1Representations,
Warranties, and Covenants of ECOtality.

 

ECOtality represents, warrants
and covenants to CHTET that:

 

(a)ECOtality owns all
right title and interest in the Blink API, the Licensed Patents, and the Marks;

 

(b)ECOtality has the full
right, power, and authority to enter into this Agreement and grant the rights contained herein;

 

(c)The execution, delivery,
and performance of this Agreement by ECOtality has been duly and properly authorized by all necessary entity actions on the part
of ECOtality;

 

(d)This Agreement constitutes
the valid and binding obligation of ECOtality, enforceable in accordance with its terms;

 

(e)Neither the execution,
delivery nor performance of this Agreement by ECOtality shall conflict with any license or other rights granted by ECOtality to
any other party;

 

(f)The person signing
this Agreement on behalf of ECOtality has been authorized to execute this Agreement for and on behalf of ECOtality and has full
authority to so bind ECOtality; and

 

(g)ECOtality shall comply
with all applicable laws in connection with this Agreement.

 

3.2Representations,
Warranties, and Covenants of CHTET.

 

CHTET represents, warrants and
covenants to ECOtality that:

 

(a)CHTET has the full
right, power, and authority to enter into this Agreement;

 

(b)The execution, delivery,
and performance of this Agreement by the CHTET has been duly and properly authorized by all necessary entity actions on the part
of CHTET;

 

(c)This Agreement constitutes
the valid and binding obligation of CHTET, enforceable in accordance with its terms;

 

(d)Neither the execution,
delivery nor performance of this Agreement by CHTET shall conflict with any obligation of CHTET under any other agreement to which
CHTET is a party; 

 

    	 

    	 

    
  

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
 7 of 14

 

(e)CHTET confirms that
it does not have any rights, titles or interests in any to Blink Functionality, the Licensed Patents, the Marks or Blink API except
the rights, titles and interests specifically provided for under this Agreement;

 

(f)The person signing
this Agreement on behalf of CHTET has been authorized to execute this Agreement for and on behalf of CHTET and has full authority
to so bind CHTET; and

 

(g)CHTET shall ensure
that all other members of the Licensee Group shall comply with the terms of this Agreement and all applicable laws in connection
with the exercise of the rights granted under this Agreement, including with respect to the manufacture, marketing, and sale of
Covered Products.

 

3.3Disclaimer of Warranties.

 

(i)ECOTALITY DISCLAIMS ALL
WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE BLINK API, THE LICENSED PATENTS, AND THE BLINK FUNCTIONALITY, OR ANY USE THEREOF,
INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS TO NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE.

 

(ii)Although ECOtality offers
no warranty with regard to the non-infringement of the Blink API, the Licensed Patents, and the Blink Functionality, ECOtality
shall indemnify, defend and hold harmless the Licensee Group and their respective directors, officers, agents, employees, members,
shareholders, and insurers from any and all direct losses, claims, damages, costs and expenses (including reasonable attorney’s
fees), causes of action, suits, damages or demands whatsoever, by any third party, arising out of the infringement of such third
party’s intellectual property rights by the Blink Functionality, the Blink API, the Licensed Patents, and the Marks, with
the total amount of all such indemnification available to the Licensee Group capped at an amount equal to the License Fee.

 

(iii)ECOtality shall in
no event be responsible for indirect, consequential, incidental, or special losses of any kind resulting from the rights granted
under this Agreement, including, without limitation, any liability for business expenses, lost profits or other damages caused
to the Licensee Group or the hosts or end users of Covered Products.

 

3.4Limitation of Liability.

 

Unless ECOtality expressly accepts
such terms and conditions in writing, no license or sale of Covered Products by any member of the Licensee Group shall cause ECOtality
to be liable for any indirect, incidental, special or consequential damages associated with the incorporation into the Covered
Products of the Blink Functionality, or the ABB Group’s use of the Licensed Patents.

 

4.CHTET Covenants.

 

CHTET covenants to ECOtality
(for the benefit of ECOtality and its Affiliates, and not for the benefit of any other third party unrelated to ECOtality) as follows:

 

4.1Reports.

 

Upon ECOtality’s request,
but no more than once per calendar quarter, CHTET shall provide a report detailing the license and sale of the Covered Products
by the Licensee Group for the immediately past calendar quarter, with the quantity of units sold, and the names and contacts of
the parties to whom the Covered Products were sold or licensed.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
8 of 14

 

4.2Quality Standards
and Controls for Use of Marks.

 

The Licensee Group shall use
the Marks only with Covered Products. The Licensee Group shall cooperate with ECOtality in maintaining ECOtality’s control
of the nature and quality of the use of the Marks, to permit reasonable inspection of the Licensee Group’s operations and
records in connection with Licensee Group’s use of the Marks, and to supply ECOtality with specimens of all uses of the Marks
upon request (including, without limitation, specimens of all packaging, labeling, advertising and marketing materials which use
the Marks). If ECOtality determines, in its discretion, that the nature and quality of a Covered Product is such that one or more
of the Marks should not be associated with that Covered Product, then, upon notice from ECOtality, any such member of the Licensee
Group shall immediately discontinue (or shall not commence) any use of the identified Mark or Marks with that Covered Product unless
and until a different determination is made by ECOtality.

 

4.3Protection of Intellectual
Property Rights.

 

(a)In using any of the
Blink Functionality or Blink API and/or any of the Marks in connection with the promotion and sale of Covered Products, the Licensee
Group shall fully comply with the marking provisions of the applicable trademark, patent, copyright and other intellectual property
laws of all applicable jurisdictions and shall include on the Covered Products, and/or their related packaging materials, all appropriate
legal notices required by law.

 

(b)The Licensee Group
shall not do anything, or permit anything to be done, in the use of any of the Blink Functionality, Blink API, the Licensed Patents,
and/or any of the Marks, which would or could jeopardize the validity of their protection under applicable intellectual property
laws.

 

(c)If any member of the
Licensee Group becomes aware of any infringement of any of ECOtality’s intellectual property rights to any of the Blink Functionality,
Blink API, the Licensed Patents or any of the Marks, it shall promptly notify ECOtality of such infringement, providing ECOtality
with all information known to the Licensee Group regarding the infringement, and provide ECOtality with all reasonable assistance
requested by ECOtality with respect to any action ECOtality may bring regarding such infringement, with any such member of the
Licensee Group reimbursed for all reasonable and documented expenses of such.

 

(d)If ECOtality becomes
aware of any infringement of any of intellectual property rights of the Licensee Group to any portion of the Covered Products,
it shall promptly notify CHTET of such infringement, providing CHTET with all information known to the ECOtality and its Affiliates
regarding the infringement, and provide CHTET with all reasonable assistance requested by the Licensee Group with respect to any
action the Licensee Group may bring regarding such infringement, with ECOtality and its Affiliates reimbursed for all reasonable
and documented expenses of such. 

 

5.Indemnification.

 

5.1Indemnification
Obligations.

 

Unless expressly stated otherwise
in this Agreement, each Party agrees to indemnify, defend and hold harmless the other Party and its Affiliates, parent companies
and subsidiaries, and their respective directors, officers, agents, employees, insurers, advisors, members and shareholders from
any and all losses, claims, damages, costs and expenses (including reasonable attorney’s fees), causes of action, suits,
damages or demands whatsoever by any third party arising out of the promotion, sale or use of Covered Products (collectively, “Claims”),
which Claims are based on an alleged or actual breach of any of its obligations under this Agreement.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
 9 of 14

 

5.2Procedure.

 

If any claim or action shall
be brought against either Party in respect to which indemnity may be sought from the other Party pursuant to the provisions of
this Section 5 (INDEMNIFICATION), the indemnified Party shall promptly notify the indemnifying Party in writing, specifying the
nature of the claim or action and the total monetary amount sought or other such relief as is sought therein. The indemnified Party
shall cooperate with the indemnifying Party in all reasonable respects in connection with the defense of any such claim or action.
The indemnifying Party may, upon written notice thereof to the indemnified Party, undertake to conduct all proceedings or negotiations
in connection therewith, assume the defense thereof and, if it so undertakes, also undertake all other required steps or proceedings
to settle or defend any such action, including the employment of counsel and payment of all expenses; provided that, the indemnifying
Party shall keep the indemnified Party informed in a timely manner, and, without the indemnified Party’s prior approval (which
shall not be unreasonably withheld), the indemnifying Party shall not enter into, or undertake or agree to enter into, any settlement
other than a settlement that provides for a full release of all claims against the indemnified Party and requires no admission,
undertaking or payment from the indemnified Party. The indemnified Party shall have the right to employ separate counsel and participate
in the defense thereof solely at its expense. The indemnifying Party shall reimburse the indemnified Party on demand for any documented
payments made or loss suffered by the indemnified Party based upon the final and non-appealable judgment of any court of competent
jurisdiction or pursuant to a bona fide and final compromise or settlement of claims, demands or actions, with respect to any damages
to which the foregoing relates.

 

5.3Survival.

 

The indemnification provisions
of this Section shall survive the termination of this Agreement.

 

6.Confidential Information.

 

During the Term, the Parties
shall exchange certain information relating to their respective business and operations that each Party considers its proprietary
and confidential information (“Confidential Information”). Each Party shall protect the other Party’s
Confidential Information in a manner equivalent to that by which it protects its own Confidential Information, and shall not, without
the prior express written consent of the other party or as may be required by law, regulation or judicial order, disclose, reveal,
or use any such Confidential Information except as permitted by this Agreement, or unless such Confidential Information is public
information through no fault of this Party, was developed independently by this Party, or was received from a third party and this
Party had no reasonable basis for knowing such was Confidential Information of the other Party. The provisions of this Section
6 (CONFIDENTIALITY) shall survive termination of this Agreement.

 

7.Termination.

 

7.1Termination by ECOtality.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
10 of 14

 

 

ECOtality shall have the right
to terminate this Agreement and the license rights of CHTET granted hereunder upon:

 

(a) CHTET’s material
breach of this Agreement, or

 

(b) CHTET’s failure
to perform any material obligation under this Agreement,

 

unless CHTET formulates and
implements a remedial plan acceptable to ECOtality (whose approval shall not be unreasonably withheld, based upon standards of
commercial reasonableness and timeliness) within thirty (30) days after ECOtality’s notification of such to CHTET.

 

7.2Effect of Termination.

 

Upon the termination of this
Agreement, all rights granted under this Agreement to CHTET shall terminate and immediately revert to ECOtality, and CHTET shall
immediately discontinue all further use of any and all of the Blink API, Licensed Patents and the Marks, except as permitted above
in Section 2(b) (TERM).

 

8.Resolution of Disputes

 

In the event of any dispute
under this Agreement, the Parties shall first attempt to resolve their dispute by good faith negotiation, and if they do not reach
such solution within a period of 30 days, then the Parties shall submit the dispute for mediation to such mediator as the Parties
may agree upon, failing which a mediator shall be appointed by the Judicial Arbitration and Mediation Services (“JAMS”).
The mediation shall be held under the rules of JAMS and shall be conducted in San Francisco, California. If JAMS is no longer in
existence, the American Arbitration Association and its rules and procedures shall be substituted for JAMS and its rules and procedures
for all purposes under this Section 8 (RESOLUTION OF DISPUTES). The Parties shall participate in the mediation process in good
faith, and shall have a representative in attendance throughout the mediation with authority to settle the dispute. Statements
made during the mediation process shall be considered to be made in the context of settlement discussions, and shall not be admissible
in any subsequent judicial proceeding. The mutually agreed result of any such mediation shall be legally binding upon the Parties
and enforceable by judicial proceedings. Subject to the foregoing, the Parties reserve any and all rights they may have to subsequently
resort to such other judicial venues as shall be available to them in resolving disputes.

 

9.Miscellaneous

 

9.1Entire Agreement.

 

The agreement contained in this
Amendment constitutes the entire understanding of the Parties relating to the Agreement, including the license granted herein,
revokes and supersedes all prior agreements between ECOtality, CHTET, and USABB relating to such license, and is intended as a
final expression of their agreement relating to the Agreement, including the license. It may not be modified or amended except
in a writing signed by both Parties and specifically referring to this Amendment.

 

9.2Assignment.

 

Neither Party may assign or
transfer the Agreement or any of its rights or obligations, without the prior consent of the other Party. Further, CHTET may not
grant to any third party any sublicense with respect to any of the license rights of the Agreement, except as permitted by the
Agreement, or with the approval of ECOtality.

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
11 of 14

 

 

9.3Severability.

 

If any term, clause, or provision
of the Agreement, including this Amendment, is held invalid or unenforceable by a court of competent jurisdiction, such invalidity
shall not affect the validity or operation of any other term, clause or provision, and such invalid term, clause or provision shall
be deemed to be severed from the Agreement or this Amendment, as may be applicable.

 

9.4Waiver.

 

No
failure of either Party to exercise any power reserved to it by the Agreement, as restated in this Amendment, or to insist upon
strict compliance by the other Party with any obligation or condition hereunder, and no custom or practice of the Parties
at variance with the terms of this Amendment or the Agreement, shall constitute a waiver of such Party’s right to demand
exact compliance with any of the terms herein. Waiver by a Party of any particular default by the other Party shall not affect
or impair the non-defaulting Party’s rights with respect to such default or any subsequent default of the same, similar or
a different nature.

 

9.5Relationship of
the Parties.

 

Nothing in this Amendment or
the Agreement shall be deemed or construed by the Parties or by any third party as creating a partnership or joint venture between
the Parties, it being understood and agreed that no provision contained herein, and no act of the Parties, shall be deemed to create
any relationship between the Parties other than the relationship of ECOtality and licensee.

 

9.5Governing Law.

 

This Amendment and the Agreement
and the license granted hereby shall be governed by and in accordance with the laws of the State of New York, without regard to
conflict of laws principles, except where the federal laws of the United States are applicable and have precedence.

 

9.6Notices.

 

Notices or other communications
required to be given by either Party pursuant to the Agreement shall be written in English and may be delivered personally, or
sent by registered airmail (postage prepaid) or by a recognized courier service, or sent by facsimile transmission, in each case
to the address or facsimile number of the recipient set forth on the signature page hereof, or such other address or facsimile
number as may be designated by a Party by written notice to the other Party given in accordance with the terms hereof. The dates
on which notices shall be deemed to have been effectively given shall be determined as follows:

 

(a)Notices given by personal
delivery shall be deemed effectively given on the date of personal delivery (as indicated by certification of the delivery personnel);

 

(b)Notices given by registered
airmail (postage prepaid) shall be deemed effectively given on the seventh (7th) day after the date on which they were
mailed (as indicated by the postmark);

 

(c)Notices given by air
courier shall be deemed effectively given on the date of delivery (as indicated by the airway bill); and

 

    	 

    	 

    
 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
12 of 14

 

(d)Notices given by facsimile
transmission shall be deemed effectively given on the first business day following the date of transmission; provided that the
notice is also sent to the recipient by registered airmail (postage prepaid) on the same day that the notice is sent by facsimile.

 

9.7Counterparts.

 

This
Amendment may be executed in counterparts, each of which shall be deemed to be an original of this Amendment and all of which,
when taken together, shall be deemed to constitute one and the same agreement of this Amendment for the Agreement.

 

 

 

    	 

    	 

    

 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
13 of 14

 

 

IN WITNESS WHEREOF, CHTET, USABB, and ECOtality have
executed this Amendment as of the Amendment Effective Date.

 

	
        ECOTALITY, INC. (“ECOTALITY”),

        a Nevada corporation

         

         

        By: _______________________

        Name: _______________________

        Title: _______________________

         

        Notice Address:

         

        Post Montgomery Center

        One Montgomery Street – Suite 2525

        San Francisco, CA  94104

        U.S.A.

         
	
        ABB TECHNOLOGY LTD. (“CHTET”),

        a Swiss entity

         

         

        By: _______________________

        Name: _______________________

        Title: _______________________

         

        By: _______________________

        Name: _______________________

        Title: _______________________

         

        Notice Address:

         

        Affolternstrasse 44

        8050 Zurich

        SWITZERLAND

        Attention: General Counsel

        

        

         

        ABB INC. (“USABB”),

        a Delaware corporation

         

         

        By: _______________________

        Name: _______________________

        Title: _______________________

         

        By: _______________________

        Name: _______________________

        Title: _______________________

         

        Notice Address:

         

        12040 Regency Parkway

        Cary, NC 27518

        U.S.A.

         

 

    	 

    	 

    

 

The
December 20, 2012 Amendment and Restatement of the ECOtality/USABB March 12, 2012 “Blink License Agreement”

December
20, 2012– EXECUTION VERSION

Page
14 of 14

 

EXHIBIT A - THE LICENSED PATENTS

 

ECOtality’s Multiport patents.

 

1.     WO 96/01518, also known as US08/275,878, also
known as PCT/CA95/00401; and

 

2.     WO 96/32768, also known as US08/419,188, also
known as PCT/CA96/00177EXCLUSIVE LICENSE AGREEMENT

 

 

THIS AGREEMENT effective December
14, 2012 (the “Effective Date”) is entered into by and between Amarantus Bioscience, Inc. a Delaware corporation, (“AMBS”),
and Memory Dx, LLC (“MDx”). The parties, intending to be legally bound, agree as follows:

 

SECTION 1 – LICENSE

 

1.1(a)Grant of Exclusive License.
For the term of this Agreement, MDx hereby grants to AMBS an exclusive worldwide license to develop, manufacture, have manufactured,
use, market, sell and import medical devices and methods under the MDx Alzheimer’s disease (“AD”) Intellectual
Property (“IP”), including but not limited to the items of intellectual property detailed on Schedule A hereto,
and to use all trademarks and copyrights related to the MDx AD IP in furtherance of such activities.

 

1.1(b)Definitions. 

 

For purposes of this
Agreement:

 

(1)“Know-How
Rights” shall mean all trade secrets and other know-how rights in and to all data, information, compositions and other
technology (including, but not limited to, formulae, procedures, protocols, techniques and results of experimentation and testing,
access to lab books and design history files) in existence on the Effective Date controlled by MDx or its affiliates or arising
thereafter to the extent necessary or useful for AMBS to make, have made, use, develop, sell, exploit or seek regulatory approval
to market a composition, a diagnostic or service, or to practice any method or process, at any time claimed or disclosed in any
issued patent or pending patent application within the Patent Rights or which otherwise relates to the Technology.

 

(2)“Patent
Rights” shall mean (a) all patents and patent applications in any country of the world that claim or cover the Technology
to the extent MDx or its affiliates heretofore or hereafter have an ownership or (sub)licensable interest therein, (b) all divisions,
continuations, continuations-in-part, that claim priority to, or common priority with, the patent applications described in clauses
(a) and (b) above or the patent applications that resulted in the patents described in clauses (a) and (b) above, and (c) all patents
that have issued or in the future issue from any of the foregoing patent applications, including utility, model and design patents
and certificates of invention, together with any reissues, renewals, extensions, substitutes or additions thereto.

 

(3)“MDx
AD IP” shall mean the Patent Rights and the Know-How.

 

(4)“Technology”
shall mean compositions, devices, technology, data and information comprising, responsible for, resulting from or relating to use
of the biomarkers of the AD IP and the tests of the same for the purpose of measuring such biomarkers, together with all improvements
and enhancements thereto, all modifications and derivatives thereof, all products comprising any of the foregoing, and all methods
of manufacture and uses of any of the foregoing, as it relates to the AD IP.

 

    	1

    	 

    
 

1.2IP Development. All
medical devices and all additional intellectual property pertaining to Alzheimer’s disease diagnosis, including all additional
patents, applications, trademarks, copyrights, inventions, trade secrets, and know-how developed by AMBS or MDx during the term
of this Agreement relating to or based in whole or in part on the MDx AD IP shall be the sole and exclusive property of the developing
party. All medical devices and all additional Intellectual Property pertaining to Alzheimer’s disease diagnosis conceived
or developed by MDx during the term of this Agreement, if any, shall be included within the scope of the exclusive license granted
hereunder to AMBS. The developing party is responsible for maintaining the patents in the agreed upon designated geographic regions
of the world.

 

1.3Term of Agreement.
The term of this Agreement shall be perpetual from the date hereof.

 

1.4Consideration. In
consideration for the license granted hereunder, the validation and technology transfer, AMBS shall issue to MDx 2,000,000 shares
of AMBS common stock, valued at the closing price of AMBS common stock on the Effective Date.

 

1.5Royalty. AMBS agrees
to pay MDx a royalty equal to 9% of the net proceeds of all sales resulting from the development of the MDx AD IP. Such royalty
payments will be capped at a total of five million United States dollars ($5M USD) during the term of this agreement. Payments
will be made on a quarterly basis.

 

1.6Assignment. AMBS may
sell, sub-license or assign this agreement to a third party at any time. In the event such sale occurs, the third party will be
solely responsible for all of the payments scheduled to be made herein.

 

SECTION 2 – MILESTONE PAYMENT
and OPTION TO PURCHASE

 

2.1Milestone Payment.
Upon successful completion and acceptance by AMBS of the Validation Study described in Schedule B, AMBS shall be required to pay
within 3 months $1,000,000 in cash or common shares of equivalent value on the date of transfer, at AMBS’ option. In the
event AMBS chooses to pay the consideration in options, the common shares issued shall have piggy-back registration rights.

 

2.2Option to Purchase AD IP.
AMBS shall have the exclusive right from the execution of this agreement, until one year after the LymPto test is available for
commercial sale in the United States, to purchase, all rights, privlidges, know-how, trademarks and other related matters pertaining
to the AD IP for $2,000,000 in cash or common shares of equivalent value on the date of transfer, at AMBS’ option. In the
event AMBS chooses to pay the consideration in options, the common shares issued shall have piggy-back registration rights.

 

    	2

    	 

    

 

SECTION 3 – VALIDATION STUDY AND
TECHNOLOGY TRANSFER

 

3.1Engagement of MDx upon Execution.
Within 10 days of execution, Amarantus agrees to engage MDx through a consulting agreement to perform the Validation Studies
outlined in Schedule B. Amarantus agrees to pay $15,000 to MDx initially, $15,000 in 30 days following the execution of this agreement,
and $20,000 in 60 days following the execution of this agreement to prepare the laboratory, assist in fund raising, and other services
as Amarantus deems appropriate and necessary as it completes the fundraising to launch the full Validation.

 

3.2Validation Studies and Technology
Transfer. For consideration granted herewith, MDx will use good faith efforts to carry out the validation study according
to Schedule B. Each month, MDx shall submit reports in writing to AMBS on the status of the validation studies and technology
transfer. During the period of this Agreement, AMBS’s technical/scientific representative and other representatives may have
reasonable access to consult informally and formally with MDx’s technical/scientific representatives regarding the validation
studies and technology transfer and other related matters, either in person, by telephone or by electronic communications (i.e.
emails or video conferences). Amarantus, its sub-licensee or assign, agrees to engage MDx for the clinical validation study as
outlined in Sechdule B within 90 days of execution of this agreement. The Validation Studies outlined in Schedule B will be funded
according to a payment schedule to be determined by Amarantus.

 

3.3Introductions to Third Parties.
MDx will introduce Amarantus to all pharmaceutical companies in the fields of dementia and at the highest corporate levels
and will seek their clinical trial input and participation and will request a Letter of Intent ("Third Party LOI”) in
which the Third Party expresses its intent to include the IP in a clinical study focused on therapeutic intervention in dementia.
The Third Party must be of significance stature in the field of dementia therapeutics, such as Roche, Lilly, Johnson & Johnson
or the like.

 

SECTION 4 – REPRESENTATIONS AND
WARRANTIES OF MDX 

 

MDx hereby represents and warrants to AMBS
as follows:

 

4.1Organization.
MDx (i) is duly organized, validly existing and in good standing (or its equivalent) under the laws of the Arizona, (ii) has all
licenses, permits, authorizations and other consents necessary to own, lease and operate its properties and assets and to carry
on its business as it is now being conducted and (iii) has all requisite corporate or other applicable power and authority to own,
lease and operate its properties and assets and to carry on its business as it is now being conducted and presently proposed to
be conducted. MDx is duly qualified or authorized to conduct business and is in good standing (or its equivalent) as a foreign
corporation or other entity in all jurisdictions in which the ownership or use of its assets or nature of the business conducted
by it makes such qualification or authorization necessary.

 

4.2Authorization;
Validity of Agreement. MDx has all requisite corporate power and authority to execute and deliver this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and performance by MDx of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by the Board of Directors of MDx and no other action on the part
of MDx or any of its stockholders or subsidiaries is necessary to authorize the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by MDx and is a valid
and binding obligation of MDx, enforceable against MDx in accordance with its terms, except as such enforcement is limited by bankruptcy,
insolvency and other similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity.

 

    	3

    	 

    
 

4.3Consents
and Approvals; No Violations. Neither the execution, delivery or performance of this Agreement by MDx nor the consummation
of the transactions contemplated hereby will (i) violate any provision of its certificate of incorporation or by-laws; (ii) violate,
conflict with or result in a breach of any provision of, or constitute a default (or an event which, with notice or lapse of time
or both, would constitute a default) under, require the consent of or result in the creation of any encumbrance upon any of the
properties of MDx or any of its subsidiaries under any material note, bond, mortgage, indenture, deed of trust, license, franchise,
permit, lease, contract, agreement or other instrument to which MDx or any its subsidiaries or any of their respective properties
may be bound; (iii) require any consent, approval or authorization of, or notice to, or declaration, filing or registration with,
any governmental entity by or with respect to MDx or any of its subsidiaries; or (iv) violate any order, writ, judgment, injunction,
decree, law, statute, rule or regulation applicable to MDx or any of its subsidiaries or any of their respective properties or
assets (See Schedule C).

 

4.4Independence.
The consent of, or the delivery of notice to or filing with, any party to a material contract is not required for the execution
and delivery by MDx of this Agreement or the consummation of the transactions contemplated under the Agreement.

 

4.5Patents
and Other Intangible Assets. MDx (i) owns, free and clear
of all liens, all patents, trademarks, copyrights, inventions, trade secrets, and know-how related to or comprising
the MDx AD IP, (ii) has not sold or granted to any third party any rights in the MDx AD IP, and (iii) has the right to use such
intellectual property without infringing upon or otherwise acting adversely to the right of any
person under or with respect to any of the foregoing. All of the MDx AD IP can and will be licensed by MDx to AMBS upon the terms
of this Agreement without the consent of any Person other than AMBS. All of the MDx AD IP is currently in full force and MDx represents
that it has no knowledge of any abandonments or other potential problems with the MDx AD IP that it has not made AMBS aware of.

 

4.6Shares
To Be Issued To MDx. With respect to the shares of common stock to be issued to MDx as consideration hereunder (the “Shares”),
MDx represents and warrants to AMBS the following:

 

		(a)	MDx acknowledges that an investment in the Shares involves a high degree of risk in that AMBS does
not currently generate revenue and may require substantial funds to pursue its business plan;

 

    	4

    	 

    
 

		(b)	MDx recognizes that an investment in the Shares is highly speculative and only investors who can
afford the loss of their entire investment should consider investing in AMBS and the Shares;

 

		(c)	MDx and its officers and directors have such knowledge and experience in finance, securities, investments,
including investment in unregistered securities, and other business matters so as to be able to protect its interests in connection
with this transaction;

 

		(d)	MDx is an "Accredited Investor" as defined in Rule 501 of Regulation D promulgated under
the Securities Act of 1933, as amended;

 

		(e)	MDx acknowledges that only a limited market for the Shares presently exists and accordingly MDx
may not be able to liquidate its investment;

 

		(f)	MDx acknowledges that the Shares are subject to significant restrictions on transfer as imposed
by state and federal securities laws, including but not limited to a minimum holding period of at least six (6) months;

 

		(g)	MDx hereby acknowledges (i) that this offering of Shares has not been reviewed by the United States
Securities and Exchange Commission ("SEC") or by the securities regulator of any state; (ii) that the Shares are being
issued by AMBS pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933; and (iii) that
the certificate evidencing the Shares received by MDx will bear a legend in substantially the following form:

 

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. WITHOUT SUCH REGISTRATION,
SUCH SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED AT ANY TIME WHATSOEVER UNLESS IN THE OPINION OF COUNSEL SATISFACTORY TO
THE COMPANY REGISTRATION IS NOT REQUIRED FOR SUCH TRANSFER AND THAT SUCH TRANSFER WILL NOT BE IN VIOLATION OF THE APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR ANY RULE OR REGULATION PROMULGATED THEREUNDER.

 

		(h)	MDx is acquiring the Shares as principal for MDx's own benefit;

 

		(i)	MDx is not aware of any advertisement of the Shares or any general solicitation in connection with
any offering of the Shares;

 

		(j)	MDx acknowledges and agrees that the AMBS has previously made available to MDx the opportunity to ask questions of and to receive
answers from representatives of AMBS concerning AMBS and the Shares, as well as to conduct whatever due diligence MDx, in its discretion,
deems advisable.

 

    	5

    	 

    
 

		(k)	MDx agrees to vote the Shares issued at the recommendation of the Board of Directors of AMBS and also agree to allow the CEO
of AMBS to vote such Shares on MDx’s behalf.

 

SECTION 5 – REPRESENTATIONS AND
WARRANTIES OF AMBS

 

AMBS hereby represents and warrant to MDx
as follows:

 

5.1Organization.
AMBS (i) is duly organized, validly existing and in good standing (or its equivalent) under the laws of the State of Delaware,
(ii) has all licenses, permits, authorizations and other consents necessary to own, lease and operate its properties and assets
and to carry on its business as it is now being conducted and (iii) has all requisite corporate or other applicable power and authority
to own, lease and operate its properties and assets and to carry on its business as it is now being conducted and presently proposed
to be conducted. AMBS is duly qualified or authorized to conduct business and is in good standing (or its equivalent) as a foreign
corporation or other entity in all jurisdictions in which the ownership or use of its assets or nature of the business conducted
by it makes such qualification or authorization necessary.

 

5.2Authorization;
Validity of Agreement. AMBS has all requisite corporate power and authority to execute and deliver this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and performance by AMBS of this Agreement and the consummation
of the transactions contemplated hereby have been duly authorized by the Board of Directors of AMBS and no other action on the
part of AMBS or any of its stockholders or subsidiaries is necessary to authorize the execution and delivery of this Agreement
and the consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by AMBS and is
a valid and binding obligation of AMBS, enforceable against AMBS in accordance with its terms, except as such enforcement is limited
by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors’ rights generally and by general
principles of equity.

 

5.3Shares
To Be Issued To MDx. With respect to the shares of common stock to be issued to MDx as
consideration hereunder (the “Shares”), AMBS represents and warrants to MDx that, upon issue, the Shares will
be duly and validly issued, fully paid and non-assessable common stock in the capital of AMBS.

 

5.4Fairness
Opinion. MDx and AMBS represents that the Parties do not require a fairness opinion to execute this Agreement or transfer
the License.

 

SECTION 6 – INDEMNIFICATION AND RELATED MATTERS

 

6.1Indemnification.
MDx shall indemnify and hold harmless AMBS, and AMBS shall indemnify and hold harmless MDx, (collectively, the “Indemnified
Parties”), and shall reimburse the Indemnified Parties for, any loss, liability, claim, damage, expense (including, but
not limited to, costs of investigation and defense and reasonable attorneys’ fees) (collectively, “Damages”)
arising from or in connection with (a) any inaccuracy, in any material respect, in any of the representations and warranties made
in this Agreement or in any disclosure schedule thereto, or any actions, omissions or statements of fact inconsistent with any
such representation or warranty, (b) any failure to perform or comply in any material respect with any covenant or agreement in
this Agreement, (c) taxes attributable to any transaction or event occurring on or prior to the date of this Agreement, or (d)
any litigation, action, claim, proceeding or investigation by any third party relating to or arising out of the business or operations
of the respective parties prior to the date hereof.

 

    	6

    	 

    
 

6.2Survival.
All representations, warranties, covenants and agreements of the Parties contained in this Agreement or in any instrument delivered
pursuant to this Agreement shall survive the termination of the initial term of this Agreement.

 

6.3Bankruptcy.
In the event MDx declares bankruptcy at any time during the term of this agreement, ownership of all MDx AD IP immediately
becomes the sole property of AMBS, and AMBS shall have a right of first refusal to purchase all equipment or assets required to
prosecute the MDx AD IP. MDx must notify AMBS at least five (5) business days prior to filing for bankruptcy.

 

6.4Notice
of Claims.

 

(a)If
an Indemnified Party shall assert a claim for indemnification pursuant to Section 6.1, such Indemnified Party shall submit to the
indemnitor a written claim stating: (i) that an Indemnified Party incurred or reasonably believes it may incur Damages and the
amount or reasonable estimate thereof of any such Damages; and (ii) in reasonable detail, the facts alleged as the basis for such
claim and the section or sections of this Agreement alleged as the basis or bases for the claim. 

 

(b)In
the event that any action, suit or proceeding is brought against any Indemnified Party with respect to which a party may have liability
under this Section 6, the indemnitor shall have the right, at its cost and expense, to defend such action, suit or proceeding in
the name and on behalf of the Indemnified Party; provided, however, that the Indemnified Party shall have the right
to retain its own counsel, with fees and expenses paid by indemnitor, if representation of the Indemnified Party by counsel retained
by the indemnitor would be inappropriate because of actual or potential differing interests between indemnitor and the Indemnified
Party. In connection with any action, suit or proceeding subject to this Section 6, the parties agree to render to each other such
assistance as may reasonably be required in order to ensure proper and adequate defense of such action, suit or proceeding. An
indemnitor shall not, without the prior written consent of the applicable Indemnified Parties, which consent shall not be unreasonably
withheld or delayed, settle or compromise any claim or demand if such settlement or compromise does not include an irrevocable
and unconditional release of such Indemnified Parties for any liability arising out of such claim or demand.

 

    	7

    	 

    

 

SECTION 7 –
TERM AND TERMINATION

 

7.1This
Agreement shall be perpetual from its date of execution unless terminated in accordance with the provision of this section.

 

7.2If
MDx is unable to meet its obligations under Section 3 and shall fail to remedy these failures within thirty (30), ABMS may
terminate this Agreement upon thirty (30) days written notice. Upon termination, MDx shall immediately return all common stock
granted to MDx under the terms of this Agreement.

 

7.4No rights
or obligations survive termination of this Agreement.

 

SECTION 8 – NOTICES 

 

All notices, requests, demands, claims,
and other communications hereunder shall be in writing. Any notice, request, demand, claim or other communication hereunder shall
be deemed duly delivered four business days after it is sent by registered or certified mail, return receipt requested, postage
prepaid, or one business day after it is sent for next business day delivery via a reputable nationwide overnight courier service,
in each case to the intended recipient as set forth below:

 

If to MDx:

Memory Dx, LLC

ATTN: William Gartner

2343 W. University Dr.

Suite 105

Phoenix, AZ 85281

 

If to AMBS:

Amarantus Bioscience, Inc.

Attn: Gerald Commissiong

675 Almanor Ave.

Sunnyvale, CA 94085

 

SECTION 9 – MISCELLANEOUS

 

9.1Amendments. Subject to applicable
law, this Agreement may be amended or modified by the parties hereto only by written agreement executed by each party to be bound
thereby and delivered by duly authorized officers of the parties hereto.

 

9.2Entire Agreement. This Agreement
and the exhibits attached hereto or referred to herein constitute the entire agreement of the parties hereto, and supersede all
prior agreements and undertakings, both written and oral, among the parties hereto, with respect to the subject matter hereof and
thereof.

 

9.3Severability. If any term
or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all
other conditions and provisions of this Agreement will nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto will negotiate
in good faith to amend or modify this Agreement so as to effect the original intent of the parties as closely as possible in an
acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible.

 

    	8

    	 

    
 

9.4Successors and Assigns; Assignment.
This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.
Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated by any of the parties
hereto without the prior written approval of all parties.

 

9.5No Third Party Beneficiaries.
Nothing herein expressed or implied shall be construed to give any person other than the parties hereto (and their successors and
assigns as permitted herein) any legal or equitable rights hereunder.

 

9.6Counterparts; Delivery by Facsimile.
This Agreement may be executed in multiple counterparts, and by the different parties hereto in separate counterparts, each of
which when executed will be deemed to be an original but all of which taken together will constitute one and the same agreement.
This Agreement and each other agreement or instrument entered into in connection herewith or therewith or contemplated hereby or
thereby, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or by electronic
mail, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same
binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto
or to any such agreement or instrument, each other party hereto or thereto shall re-execute original forms thereof and deliver
them to all other parties. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or
electronic mail to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated
through the use of a facsimile machine or electronic mail as a defense to the formation or enforceability of a contract and each
such party forever waives any such defense.

 

9.7Governing Law. This Agreement
and the agreements, instruments and documents contemplated hereby shall be governed by and construed and enforced in accordance
with the laws of the State of California without regard to its conflicts of law principles.

 

9.8Interpretation.

 

(a)When
a reference is made in this Agreement to a section or article, such reference shall be to a section or article of this Agreement
unless otherwise clearly indicated to the contrary.

 

(b)Whenever
the words “include”, “includes” or “including” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation.”

 

(c)The
words “hereof”, “hereby”, “herein” and “herewith” and
words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement, and article, section, paragraph, exhibit and schedule references are to the articles, sections, paragraphs,
exhibits and schedules of this Agreement unless otherwise specified.

 

    	9

    	 

    
 

(d)The
words “knowledge,” or “known to,” or similar terms, when used in this Agreement to qualify
any representation or warranty, refer to the knowledge or awareness of certain specific facts or circumstances related to such
representation or warranty of the persons in the Applicable Knowledge Group (as defined herein) which a prudent business person
would have obtained after reasonable investigation or due diligence on the part of any such person. For the purposes hereof, the
“Applicable Knowledge Group” with respect to AMBS shall be Gerald Commissiong. For the purposes hereof, the
“Applicable Knowledge Group” with respect to MDx shall be Ira L. Goldknopf, Ph.D..

 

(e)The
word “subsidiary” shall mean any entity of which at least a majority of the outstanding shares or other equity
interests having ordinary voting power for the election of directors or comparable managers of such entity is owned, directly or
indirectly by another entity or person.

 

(f)For
purposes of this Agreement, “ordinary course of business” means the ordinary course of business consistent with
past custom and practice (including with respect to quantity and frequency).

 

(g)The
plural of any defined term shall have a meaning correlative to such defined term, and words denoting any gender shall include all
genders. Where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding meaning.

 

(h)A
reference to any legislation or to any provision of any legislation shall include any modification or re-enactment thereof, any
legislative provision substituted therefor and all regulations and statutory instruments issued thereunder or pursuant thereto,
unless the context requires otherwise.

 

(i)The parties
hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent
or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

 

    	10

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed on the date first written above.

 

	 	 	Amarantus Bioscience, Inc.
	 	 	 
	 	 	 
	 	 	By:	
        /s/ Gerald Commissiong

	 	 	Name:	Gerald Commissiong
	 	 	Title:	President & CEO
	 	 	 
	 	 	 
	 	 	Memory Dx, Inc.
	 	 	 
	 	 	/s/ William Gartner
	 	 	Name:	William Gartner
	 	 	Title:	President & CEO
	 	 	 	 	 

 

 

    	11

    	 

    

 

Schedule
A – MDx Alzheimer’s Disease Diagnostic IP 

 

LymPro Test Intellectual Property

 

Issued Patents

 

		·	DE 19936035 Germany 05/13/2003

 

		·	DE 10349162 Germany 10/22/2003

 

		·	223322 India 09/09/2008

 

		·	2006/03178 South Africa 07/25/2007

 

		·	EP 1876449 (AI) Germany 07/07/2006

 

		·	PCT/EP2004/010889 PCT 09/24/2004

 

		·	PCT/EP2007/006028 PCT 07/06/2007

 

Country Specific Filings (not issued)

 

	Australia	Mexico
	Brazil	New Zealand
	Canada	Norway
	China	Philippines
	Europe	Russia
	Israel	Serbia/Montenegro
	Japan	Singapore
	South Korea	United States

 

Know-How, Data and Methods

 

		·	All Laboratory Protocols and Methods

 

		·	All Quality Control Processes

 

		·	All Clinical Study Data and Findings to Date

 

		·	All published papers and posters

 

    	12

    	 

    
 

Schedule B 

 

Outline of Amarantus LymPro Clinical
Study

LymPro Test Foundation

 

The Study will use either the antibody cocktails shown below,
or a rationalized six tube cocktail matrix. The final decision is pending a full evaluation of the impacts of switching CD19 to
the PerCP-Cy5.5 channel. 

 

	Tube	Antibody Cocktail	Format	Condition	File#
	1	IgG1 / IgG1 / CD45 / IgG1	FITC/PE/PerCP-Cy5.5/APC	Control	001
	2	CD8 / CD69 / CD3/ CD4	FITC/PE/PerCP-Cy5.5/APC	Unstimulated	002
	3	CD14 / CD69 / CD45 / CD19	FITC/PE/PerCP-Cy5.5/APC	Unstimulated	003
	4	CD8 / CD28  / CD45 / CD4	FITC/PE/PerCP-Cy5.5/APC	Unstimulated	004
	5	CD45RA+/CD45RO+/CD3/CD4	FITC/PE/PerCP-Cy5.5/APC	Unstimulated	005
	6	CD8 / CD69 / CD3/ CD4	FITC/PE/PerCP-Cy5.5/APC	Stimulated	006
	7	CD14 / CD69 / CD45 / CD19	FITC/PE/PerCP-Cy5.5/APC	Stimulated	007
	8	CD8 / CD28 / CD45 / CD4	FITC/PE/PerCP-Cy5.5/APC	Stimulated	008
	
        NOTE: Markers showing statistically significant results in
        prior studies are presented in Bold. 

        LymPro Scores use continuous, discrete and ratios of several
        of the above markers

Table 1: LymPro Antibody Cocktail

Non-Clinical Study

Non-Clinical development will occur prior to clinical enrollment.
This effort shall focus on developing systems, procedures, standards, and sample to ensure long-term test stability and repeatability.
Additionally, these procedures will aid in reducing inter-operator, inter-instrument and inter-lab variability to aid in broad
test dissemination.

Clinical Study

Enrollment Criteria and Targets:

Table 1 shows the eligibility criteria to be used during
both stages of the clinical study. Table 2 shows the minimum enrollment for each stage of the Study and an approximate enrollment
by Study Cohort. All Subjects will be randomly assigned to either the Stage I Training Set or Stage II Blind Set upon enrollment.
Enrollment tables are based on the number of subjects needed for a 80% probability of detecting a 1 standard deviation difference
between study cohorts. MDx may exceed these enrollment numbers upon written agreement by the parties.

 

    	13

    	 

    
 

	Group	Eligibility Criteria	Ineligibility Criteria
	
        AD Probable

         

         
	
        DSMIIIR “Dementia of the Alzheimer type” (DAT)
        or NINCDS-ADRDA “probable” AD 

        Mini Mental State Examination (MMSE) of 26 or lower

        Patient must be greater than 55 years of age

        Patient must sign a consent form. If the patient’s
        status precludes giving informed consent, informed consent may be given by the patient’s legal representative
	
        No recent infection or other illnesses 

        Diagnosis of probable or possible Alzheimer’s in combination
        with other dementia. 

        Significant other medical problems, e.g., active malignancy,
        class 3 or 4 heart failure (NYHA), end stage renal, liver, or lung disease. Psychiatric causes of qualifying MMSE score 

	Table 2: Study Eligibility Criteria
	 	 	 
	
        Other Dementia

         

         
	
        Clinical Diagnosis of Vascular dementia, dementia due to
        Parkinson’s disease, Lewy Body dementia, Picks / Frontal Lobe dementia, or dementias due to primary or secondary brain tumor,
        subdural hematoma, slowly progressive or normal-pressure hydrocephalus, neurological conditions (e.g., multiple sclerosis), or
        endocrine conditions (hypothyroidism, hypercalcemia)

         

        Mini Mental State Examination (MMSE) of 26 or lower

        Patient must be greater than 55 years of age

        Patient must sign a consent form. If the patient’s
        status precludes giving informed consent, informed consent may be given by the patient’s legal representative
	
        No recent infection or other illnesses

        Significant other medical problems, e.g., active malignancy,
        class 3 or 4 heart failure (NYHA), end stage renal, liver, or lung disease.

        AAMI, MCI, dementia due to head trauma, nutritional conditions
        (deficiency of thiamin, niacin, or vitamin B12), effects of medications (e.g., benzodiazepines, ß blockers, diphenhydramine),
        toxic effect of long-standing substance abuse, especially alcohol abuse, other infectious conditions (HIV, neurosyphilis, Cryptococcus),
        or derangements of renal and hepatic function

	
        Cognitively Intact

         

         
	
        Must be of greater than 55 years of age

        Age matched to AD probable or Other Dementia group

        Patient must sign a consent form. If the patient’s
        mental status precludes his/her giving informed consent, written informed consent may be given by the patient’s legal representative
	
        No recent history of mental illness (< 2 years)

        No recent infection or other illnesses

        Significant other medical problems, e.g., active malignancy,
        class 3 or 4 heart failure (NYHA), end stage renal, liver, or lung disease.

 

    	14

    	 

    
 

Table 2: Study Eligibility Criteria (continued)

 

	Enrollment Targets
	 	AD Probable	Other Dementias	Cognitively Intact	Total
	Stage I, Training Data	40	40	30	110
	Stage II, Blind	20	20	15	55

Table
3: Minimum Total Enrollment and Approximate Breakdown by Cohort 

	
        End Points

        This study will not make comparison to the “gold standard”
        of Alzheimer’s diagnosis, neuropathology, as the time and expense such studies would require would far exceed the scope of
        the proposed effort. As a result, the study’s endpoint will be defined in terms of co-positivity and co-negativity with expert
        clinical diagnosis. Results therefore will be properly expressed as "co-positivity" and "co-negativity" as
        opposed to sensitivity and specificity. 

        Human Subject Protection: 

        MDx will obtain IRB approval either through Western IRB,
        Banner IRB (where MDx anticipate recruiting the majority of study subjects), or a similar IRB. All participants will sign informed
        consent agreements prior to undergoing any evaluations or donating any samples. Should the patient’s mental status preclude
        informed consent, the authorized staff member will include the potential subject’s authorized representative throughout the
        process, establish the subject’s assent and obtain informed consent from the subject’s authorized representative.

         
	
         

        

Figure 1: AD Dx Venn Diagram
        

  

    	15

    	 

    

 

LymPro Test® Development Work Plan

 

Summary:

The LymPro Test® is a blood test for the detection of
Alzheimer’s disease. Our objective is to complete the development and clinical use study for the LymPro Test to prepare it
for sale as a Laboratory Developed Test under CLIA. The major tasks required are provided in the following table with the expected
costs and time required for each task. Some of the projected timelines are estimated maximums.

 

	 	Task Description	Cost	Time
	1	Complete Clinical Study Design and get IRB Approval	$7,500	1 month
	2	Clinical Study Patient Recruiting Estimate for 250 subjects at $900 per subject	$225,000	15 months
	3	Laboratory instrument startup and validation. Includes service contract, reagents, labor and instrument stability verification	$80,000	2 months
	4	Laboratory analysis of clinical study samples, including: reagents, and labor	$750,000	16 months
	5a	Statistical Review of Clinical Study Results	$130,000	2 months
	5b	Validation Study for CLIA LDT launch	$30,000
	 	 	 	 
	 	Total Cost and Elapsed Time      	$1,222,500	18 months

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]